Literature DB >> 4051321

The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables.

O Eliasson, A C Degraff.   

Abstract

Multiple criteria for obstruction and reversibility are being used at present to define patient populations for bronchodilator studies. In order to establish whether the use of different criteria would result in variation in results, we evaluated 4 criteria for obstruction and found that the outcome of a bronchodilator trial, mean response, will depend on the definition of obstruction used. The obstruction criteria evaluated were: (1) FEV less than lower 95% confidence limit (CL) of predicted, (2) FEV1/FVC% less than lower 95% CL, (3) FEV1 between 500 and 1,500 ml, and (4) FEV1 less than 60% of predicted. Patients selected by criterion (1) had 8.9% FEV1 response, whereas those selected by criterion (3) had 14% FEV1 response. This difference resulted mostly from the difference in the degree of obstruction among the groups as well as the effect of regression to the mean compounded by calculating the results as percent of baseline. Also, it appears the use of obstruction criteria based on the absolute value of the FEV1 or on predicted FEV1 may create an age and height bias for bronchodilator response, this being of minimal clinical importance, though. Finally, we found that the conventional reversibility criterion: 15% improvement of the initial FEV1, could be misleading. This criterion could not be used to define disease, and when it was applied to a patient population it resulted in the selection of the most obstructed subjects, which is a contradiction of the very definition of reversibility.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4051321     DOI: 10.1164/arrd.1985.132.4.858

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  23 in total

1.  On the meaning and utility of diagnostic terms: Special reference to bronchopulmonary abnormalities in the horse.

Authors:  T L Whiting; D B Tesarowski
Journal:  Can Vet J       Date:  1988-10       Impact factor: 1.008

2.  Predicted values: how should we use them?

Authors:  M R Miller; A C Pincock
Journal:  Thorax       Date:  1988-04       Impact factor: 9.139

3.  Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest.

Authors:  E Boni; L Corda; D Franchini; P Chiroli; G P Damiani; L Pini; V Grassi; C Tantucci
Journal:  Thorax       Date:  2002-06       Impact factor: 9.139

4.  The American Thoracic Society's spirometric criteria alone is inadequate in asthma diagnosis.

Authors:  John A Gjevre; Thomas S Hurst; Regina M Taylor-Gjevre; Donald W Cockcroft
Journal:  Can Respir J       Date:  2006 Nov-Dec       Impact factor: 2.409

5.  Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.

Authors:  H A Kerstjens; P L Brand; P H Quanjer; B A van der Bruggen-Bogaarts; G H Koëter; D S Postma
Journal:  Thorax       Date:  1993-07       Impact factor: 9.139

6.  Terbutaline in COPD comparison between Turbuhaler and chlorofluorocarbon (CFC) inhaler.

Authors:  H Formgren; A Sjökvist; E Ståhl; J E Wirén
Journal:  Lung       Date:  1994       Impact factor: 2.584

7.  Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program.

Authors:  Sunita Sharma; Augusto A Litonjua; Kelan G Tantisira; Anne L Fuhlbrigge; Stanley J Szefler; Robert C Strunk; Robert S Zeiger; Amy J Murphy; Scott T Weiss
Journal:  J Allergy Clin Immunol       Date:  2008-10-10       Impact factor: 10.793

8.  Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction.

Authors:  F W Dekker; A C Schrier; P J Sterk; J H Dijkman
Journal:  Thorax       Date:  1992-03       Impact factor: 9.139

9.  Emphysematous changes assessed by selective alveolobronchography and bronchodilator response in chronic airflow obstruction.

Authors:  H Koyama; K Nishimura; T Mio; T Izumi
Journal:  Lung       Date:  1994       Impact factor: 2.584

10.  Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma.

Authors:  Daphne C Richter; James R Joubert; Haylene Nell; Mace M Schuurmans; Elvis M Irusen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.